Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• composition Qf A Potent HCV Inhibitor for Oral Administration
• the invention relates to a pharmaceutical composition of a potent hepatitis C viral (HCV) inhibitor for oral administration.
• HCV hepatitis C viral
• Compound (1) is known as a selective and potent inhibitor of the HCV NS3 serine protease.
• Compound (1) is a zwitterionic compound and falls within the scope of the acyclic peptide series of HCV inhibitors disclosed in U.S. Patents 6,323,180, 7,514,557 and 7,585,845.
• Compound (1) is disclosed specifically as Compound # 1055 in U.S. Patent 7,585,845, and as Compound # 1008 in U.S. Patent 7,514,557 .
• Compound (1) can be prepared according to the general procedures found in the above-cited references, which are herein incorporated by reference.
• Preferred forms of Compound (1) include the crystalline forms, in particular the crystalline sodium salt form, which can be prepared as described in the examples section herein.
• Compound (1) may also be known by the following alternate depiction of its chemical structure, which is equivalent to the above-described structure'
• U.S. Patent 6,531,139 and the corresponding published International Application WO9906024 describe a pharmaceutical composition which comprises a lipophilic, pharmaceutically active agent, a lipid which is a mixture of mono- and diglycerides, a solvent and a surfactant.
• a number of pharmaceutically acceptable solvents are listed, including polyethylene glycol, although propylene glycol is stated to be the preferred solvent.
• a number of pharmaceutically acceptable surfactants are listed, with Cremophor RH40® or Cremophor EL® being preferred. Vitamin E TPGS is not included in the listing of pharmaceutically acceptable surfactants.
• U.S. Patent 6,231,887 and the corresponding published International Application WO9906044 describe a pharmaceutical composition which comprises a pyranone as a pharmaceutically active agent, a basic amine, a solvent and a surfactant, and optionally a lipid which is a mixture of mono- and diglycendes.
• a number of pharmaceutically acceptable solvents are listed, including polyethylene glycol, although propylene glycol is stated to be the preferred solvent.
• a number of pharmaceutically acceptable surfactants are listed, with Cremophor RH40® or Cremophor EL® being preferred. Vitamin E TPGS is not included in the listing of pharmaceutically acceptable surfactants. It is indicated that the composition thus described, which is a liquid, may be used to fill capsules for oral administration, and that it may also be in the form of a liquid solution for oral, parenteral, rectal or topical application.
• U.S Patent 6,555,558 and the corresponding published International Application WO0236110 describe a pharmaceutical composition which comprises a pyranone protease inhibitor (specifically including but not limited to tipranavir), a surfactant, a polyethylene glycol solvent, a lipid which is a mixture of mono- and diglycerides and, optionally, a basic amine.
• the composition is substantially free of ethanol and propylene glycol.
• a number of pharmaceutically acceptable surfactants are listed, with Cremophor EL® being preferred. Vitamin E TPGS is not included in the listing of pharmaceutically acceptable surfactants. It is indicated that the composition thus described, which is a liquid, is particularly suitable for filling soft gelatin capsules intended for oral administration.
• Vitamin E-TPGS (d- Alpha Tocopheryl Polyethylene Glycol 1000 Succinate) is a water soluble form of vitamin E and has been recognized as an excipient to promote emulsification of lipophilic substances, acting as a non-ionic surfactant, and in improving the bioavailability of certain drugs.
• WO9531217 describe the use of tocopherols as solvents and/or surfactants of drugs that are substantially insoluble in water, in particular for the preparation of topical formulations.
• Use of Vitamin E-TPGS is specifically mentioned at pages 7-8 and 12 as an surfactant for use in formulations containing high levels of alpha. -tocopherol as the lipid layer.
• Vitamin E-TPGS can be used for the enhanced delivery of lipophilic compounds as a self-emulsifymg preconcentrate formulation comprising a) a lipophilic drag (a cyclosporin is specifically exemplified), b) vitamin E-TPGS and c) a lipophilic phase.
• Typical examples of formulations disclosed, such as Examples 2 and 4, contain less than 14% w/w Vitamin E-TPGS as an surfactant, a lipid layer and the drug. There is no reference to formulation of HIV protease inhibitors.
• the present invention provides a pharmaceutically acceptable oral formulation of Compound (1), or a pharmaceutically acceptable salt thereof, in the form of a solution for oral administration.
• the formulation comprises at least one solvent to enhance solubility of the drug and at least one surfactant with a hydrophilic/lipophilic balance (HLB) > 10 added to maintain the drug substance in a dissolved state upon dilution in simulated GI fluids.
• HLB hydrophilic/lipophilic balance
• the formulation of the invention can further contain water as a co-solvent and taste masking components, such as sweeteners and flavors. An antioxidant may be added to prevent drug substance oxidation.
• Table I Two examples of composition of this formulation, in two different strengths, are shown in Table I.
• the drug substance in combination with the surfactant may solidify or may not be fluid enough for oral administration.
• One of the objects of the present invention was to obtain a solution well adapted for oral administration in an unencapsulate form. It is preferred that such formulation would be flowable at room temperature, thereby rendering it suitable for oral administration in a liquid form and to facilitate dosing. It has been found that the addition of at least one cosolvent in combination with the surfactant helps to maintain the present formulation as a liquid flowable solution at room temperature, thereby achieving the advantages mentioned above.
• the drug substance compound is present in the composition at a concentration level such as to provide flexibility of dosing by allowing one to change the dose administered by changing the volume. This flexibility with respect to dosing provides a wide range of dosing from a low dose for administration to small children to a high dose for adults who are unable to swallow a solid dosage form.
• composition is substantially free of lipid.
• the active ingredient, Compound (1), or a pharmaceutically acceptable salt thereof is present in an amount from 1 % to 40% by weight of the total composition with preferred amounts from 2% to 10% by weight of the total composition, and even more preferably from 2% to 8% by weight of the total composition
• Preferred forms of Compound (1) that may be used in the formulation include its crystalline forms, in particular the crystalline sodium salt form of Compound (1).
• Surfactants suitable for use in the composition of the present invention include surfactants having a hydrophilic/lipophihc balance (HLB) of greater than 10.
• suitable surfactants include Vitamin E TPGS, a polyethoxylated castor oil (e.g. CREMOPHOR ® EL), a polyoxyl hydrogenated castor oil (e.g. CREMOPHOR ® RH), a polyoxyethylene sorbitan fatty ester (e.g. polysorbate 80), a caprylocaproyl macrogolglyceride (e.g. LABRASOL ® ) or a mixture thereof.
• a preferred surfactant is Vitamin E TPGS.
• the surfactant comprises 2% to 50% by weight of the total composition with preferred amounts from 10% to 30% by weight of the total composition.
• Different ranges of surfactant and drug substance (DS) should result in different aqueous dispersions. Examples of these compositions are showed in Table II below:
• compositions comprising Vitamin E TPGS (surfactant) to Compound (1) sodium salt (drug substance) ratios greater than or equal to 2.7 produced clear dispersion upon dilution in simulated gastric fluid
• compositions comprising ratios from 1.4 to 2 produced slightly turbid or translucent dispersions and compositions comprising ratios equal to or lower than 1 produce a suspension having a turbid or "milky" appearance upon dilution in simulated gastric fluid.
• a higher surfactant to drug substance ratio is necessary to provide a clear dispersion.
• compositions comprising surfactant to drug substance ratios from 1.4 to 2.9 produced slightly turbid or translucent dispersions and only at the higher ratio of 4.3 was a clear dispersion obtained.
• additional embodiments of the present invention may include:
• compositions wherein the weight ratio of surfactant to drug substance is greater than or equal to 1.4;
• compositions wherein the weight ratio of surfactant to drug substance is greater than or equal to 2.7; and compositions wherein the weight ratio of surfactant to drug substance is greater than or equal to 4.3
• Additional preferred embodiments under embodiments (a) to (c) above include:
• compositions contain drug substance in an amount less than or equal to 4.6% and the weight ratio of surfactant to drug substance is greater than or equal to 2.7;
• compositions wherein under embodiment (c) above the compositions contain drug substance in an amount less than or equal 6.3% and the weight ratio of surfactant to drug substance is greater than or equal to 4.3.
• Additional preferred embodiments include any of the above embodiments (a) to (e) above wherein the surfactant is Vitamin E TPGS.
• the compositions of the present invention will form a clear, slightly turbid or translucent dispersion upon dilution in simulated gastric fluid. In another preferred embodiment, the compositions of the present invention will form a clear dispersion upon dilution in simulated gastric fluid.
• the formulation forms a clear, translucent or only slightly turbid dispersion on dilution, this is indicative that there has been no or only a limited amount of Compound (1) precipitation and that the active ingredient has remained substantially solubilized.
• Such systems are preferable in that one would generally expect them to result in a higher bioavalibility of the active ingredient upon ingestion as compared to a turbid dispersion where the active ingredient has substantially precipitated.
• the clarity of the final dispersion can be verified by well known methods in the art.
• the clarity can be determined by measuring the size of droplets and particles using laser light scattering methods (e.g. dynamic light scattering or static light scattering) which are well known in the art.
• laser light scattering methods e.g. dynamic light scattering or static light scattering
• Different ratios of surfactant to drug substance will produce different particle/droplet sizes and different levels of clarity.
• a typical value of mean particle size for a clear final dispersion can be less than 1 ⁇ m, while for a slightly turbid or turbid dispersion the value of particle sizes will be higher than 1 ⁇ m. Examples of composition of this present formulation having different clarity and droplet or particle sizes are shown in example 7.
• the composition has a mean particle size of less than 1 ⁇ m upon dilution in simulated gastric fluid.
• solvents suitable for use in the context of the present invention are propylene glycol, polypropylene glycol, polyethylene glycol (such as low molecular weight polyethylene glycol including but not limited to PEG300, 400, 600, etc.), glycerol, efhanol, triacetin, dimethyl isosorbide, glycofurol, propylene carbonate, water, dimethyl acetamide or a mixture thereof.
• at least one solvent is a low molecular weight polyethylene glycol, for example, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, or mixtures thereof.
• the preferred solvent is a mixture of water, polyethylene glycol having a mean molecular weight of greater than 300 but lower than 600 and propylene glycol. Still more preferred as solvent is a mixture of water, propylene glycol and polyethylene glycol 400. In another preferred embodiment, the solvent is a mixture of water and polyethylene glycol 400.
• the solvent, or mixture of solvents comprises 10% to 90% by weight of the total composition, with preferred amounts of 60% to 90% by weight of the total composition.
• the water co-solvent is present in the composition in an amount of 0 to 50% by weight of the total composition, more preferably from 0 to 30% by weight of the total composition, even more preferably from 5 to 20% by weight of the total composition.
• compositions of the present invention are preferably substantially free of propylene glycol.
• substantially free means less than or equal to 8% by weight, more preferably less than or equal to 2% by weight, of propylene glycol in the composition.
• the composition of the present invention does not contain any propylene glycol.
• compositions of the present invention are also preferably substantially free of amines.
• substantially free means less than or equal to 2% by weight, more preferably less than or equal to 1 % by weight, even more preferably less than or equal to 0.5% by weight, of amine in the composition.
• the composition of the present invention does not contain any amine.
• compositions in accordance with the invention are substantially free of lipid in the composition, because these compounds could have a significant influence in the taste. So by avoiding the addition or significant reduction of such substances, an appropriate palatability can be achieved, particularly for pediatric use.
• substantially free means less than or equal to 5% by weight, more preferably less than or equal to 2% by weight, of lipid in the composition.
• the composition of the present invention does not contain any lipid.
• composition in accordance with the invention optionally includes further excipients, such as antioxidants (e.g. ⁇ -tocopherol, propyl gallate, ascorbic palmitate, BHT, BHA or mixtures thereof) and/or sweetening (e.g. sucralose, accesulfame potassium, sodium saccharin, or mixtures thereof) and flavoring agents (e.g. butter toffee, buttermint, bubble gum, grape, cherry, strawberry or mixtures thereof).
• antioxidants e.g. ⁇ -tocopherol, propyl gallate, ascorbic palmitate, BHT, BHA or mixtures thereof
• sweetening e.g. sucralose, accesulfame potassium, sodium saccharin, or mixtures thereof
• flavoring agents e.g. butter toffee, buttermint, bubble gum, grape, cherry, strawberry or mixtures thereof.
• the pharmaceutical composition of the present invention comprises
• composition is substantially free of lipid, or more preferably does not contain any lipid.
• the pharmaceutical composition of the present invention comprises:
• composition 60% to 90% by weight of solvent or mixture of solvents; and wherein the composition is substantially free of lipid, or more preferably does not contain any lipid.
• the pharmaceutical composition of the present invention comprises'
• composition 60% to 90% by weight of a mixture of water, propylene glycol and polyethylene glycol 400 ; and wherein the composition is substantially free of lipid, or more preferably does not contain any lipid.
• the pharmaceutical composition of the present invention comprises:
• composition 60% to 90% by weight of a mixture of water and polyethylene glycol 400; and wherein the composition is substantially free of lipid, or more preferably does not contain any lipid.
• compositions are (1) substantially free of propylene glycol or does not contain propylene glycol, and/or (2) substantially free of an amine or does not contain an amine.
• An example of a methodology for manufacture the inventions is as follows: mix solvents at a temperature of 40 0 C - 50 0 C, add surfactant and mix. Then add the drug substance and mix until complete dissolution. Add the sweetener dissolved in water and mix. Lower the temperature up to 35-37°C, add the flavors and mix.
• the self-dispersing formulations in accordance with the present invention generate micellar solutions when mixed with aqueous media.
• the formulation can be mixed with an aqueous medium such as water, fruit juice or the like, prior to ingestion.
• the formulation can be ingested in liquid form so that it will mix with gastric fluid, forming a micelar solutions in situ.
• the Compound (1) may precipitate out of solution when the formulation is mixed with gastric fluid, resulting in the formation of a suspension having a turbid or "milky" appearance.
• compositions in accordance with the present invention are useful in the treatment of Hepatitis C viral (HCV) infection and can be administered in accordance with the general protocols as described in U.S. Patent 7,585,845.
• the skilled physician can select appropriate dosing for any particular patient by following the general dosing guidelines found in said patent publication and using sound medical judgment, taking into consideration the age, size, general health, seventy of the condition and other characteristics of the particular patient to be treated.
• Examples 1-5 describe the preparation of various crystalline forms of Compound (1)
• Amorphous Compound (1) (Batch 7, 13 8Og) was added to a 1000 ml three neck flask. Absolute ethanol (248.9g) was added to the flask. While stirring, the contents of the flask were heated at 60 degrees C/hr to ⁇ 74 degrees C (Solids do not dissolve at 74 degrees C) Water (257 4g) was then added linearly over 4 hr to the resulting slurry while stirring and maintaining the temperature at 74 degrees C After the water addition was complete, the temperature was reduced linearly to ambient temperature at 8 degrees C/hr and then held at ambient temperature for 6 hrs while stirring.
• Example 6 Pharmaceutical Compositions of Compound (1) sodium salt.
• Table V compositions of Compound (1) sodium salt oral solution comprising different ratios of Vitamin E TPGS to DS
• Table VI compositions of Compound (1) sodium salt oral solution compnsing different combination of Solvents
• Example 7 Pharmaceutical Compositions of Compound (1) sodium salt.
• Table X Compositions of Compound (1) sodium salt oral solution comprising different ratios of Vitamin E TPGS to DS

Priority Applications (24)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=41650279

Family Applications (1)

Country Status (35)

Cited By (15)

Families Citing this family (8)

Citations (3)

Family Cites Families (3)

• 2009
  • 2009-11-18 ES ES09760395.5T patent/ES2445516T3/es active Active
  • 2009-11-18 MY MYPI2011002269A patent/MY155402A/en unknown
  • 2009-11-18 RS RS20130583A patent/RS53121B/en unknown
  • 2009-11-18 AU AU2009316755A patent/AU2009316755B2/en not_active Expired - Fee Related
  • 2009-11-18 BR BRPI0921070A patent/BRPI0921070A2/pt not_active IP Right Cessation
  • 2009-11-18 PE PE2011001059A patent/PE20120032A1/es not_active Application Discontinuation
  • 2009-11-18 US US13/129,641 patent/US20120101049A1/en not_active Abandoned
  • 2009-11-18 KR KR1020117011446A patent/KR20110087297A/ko not_active Application Discontinuation
  • 2009-11-18 WO PCT/US2009/064908 patent/WO2010059667A1/en active Application Filing
  • 2009-11-18 PT PT97603955T patent/PT2358355E/pt unknown
  • 2009-11-18 MX MX2011005151A patent/MX2011005151A/es active IP Right Grant
  • 2009-11-18 CA CA2738732A patent/CA2738732A1/en not_active Abandoned
  • 2009-11-18 CN CN2009801464655A patent/CN102223875A/zh active Pending
  • 2009-11-18 SI SI200930810T patent/SI2358355T1/sl unknown
  • 2009-11-18 DK DK09760395.5T patent/DK2358355T3/da active
  • 2009-11-18 EP EP09760395.5A patent/EP2358355B1/en active Active
  • 2009-11-18 ME MEP-2013-140A patent/ME01614B/me unknown
  • 2009-11-18 EA EA201100795A patent/EA022272B1/ru not_active IP Right Cessation
  • 2009-11-18 SG SG2011036498A patent/SG171771A1/en unknown
  • 2009-11-18 PL PL09760395T patent/PL2358355T3/pl unknown
  • 2009-11-18 UA UAA201107610A patent/UA105777C2/uk unknown
  • 2009-11-18 JP JP2011537562A patent/JP5553839B2/ja not_active Expired - Fee Related
  • 2009-11-18 NZ NZ592383A patent/NZ592383A/xx not_active IP Right Cessation
  • 2009-11-20 AR ARP090104496A patent/AR074391A1/es unknown
  • 2009-11-20 TW TW98139549A patent/TWI469801B/zh not_active IP Right Cessation
  • 2009-11-20 UY UY0001032252A patent/UY32252A/es not_active Application Discontinuation
• 2011
  • 2011-03-17 ZA ZA2011/02029A patent/ZA201102029B/en unknown
  • 2011-03-21 IL IL211832A patent/IL211832A/en not_active IP Right Cessation
  • 2011-04-19 CL CL2011000878A patent/CL2011000878A1/es unknown
  • 2011-05-20 EC EC2011011065A patent/ECSP11011065A/es unknown
  • 2011-05-20 TN TN2011000258A patent/TN2011000258A1/fr unknown
  • 2011-05-20 MA MA33867A patent/MA32812B1/fr unknown
  • 2011-05-24 CO CO11063891A patent/CO6361900A2/es not_active Application Discontinuation
• 2014
  • 2014-01-24 CY CY20141100063T patent/CY1114892T1/el unknown
  • 2014-02-04 HR HRP20140097AT patent/HRP20140097T1/hr unknown
  • 2014-10-17 US US14/517,242 patent/US20150038532A1/en not_active Abandoned

Patent Citations (4)

Also Published As

Similar Documents

Legal Events